In a report released today, Steven Halper from Cantor Fitzgerald reiterated a Hold rating on Humana Inc (HUM), with a price target of $320. The company’s shares opened today at $298.29.
Halper commented:
“. We reiterate our Neutral rating on HUM shares and lower our 12-month price target to $320 from $325. This morning, February 6, the company reported 4Q18 results and provided its detailed 2019 guidance. 4Q18 adjusted EPS were above our estimate while 2019 bottom line guidance was in line with our estimate. The company had previously provided 2019 membership metrics which were unchanged. The company had also previously indicated that it expected 2019 adjusted EPS to grow above its stated long-term goal of 11-15%. The mid-point of its guidance range represents about 18% growth from reported 2018 adjusted EPS. Still, 2019 individual MA margins are unlikely to expand as much as previously expected.”
According to TipRanks.com, Halper is a top 100 analyst with an average return of 20.1% and a 64.8% success rate. Halper covers the Services sector, focusing on stocks such as WellCare Health Plans, Tivity Health Inc, and Evolent Health.
Humana Inc has an analyst consensus of Strong Buy, with a price target consensus of $376.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $355.88 and a one-year low of $260. Currently, Humana Inc has an average volume of 1.13M.
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. Most recently, in November 2018, Timothy Huval, the Chief HR Officer of HUM sold 5,165 shares for a total of $1,777,845.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humana Inc. is a health and well-being company focused on making it easy for people to achieve best health. Its strategy integrates care delivery, the member experience, and clinical & consumer insights to encourage engagement, behavior change, proactive clinical outreach, and wellness for the people.
